GlassScriptPhysician profile
Muhammad A Salahuddin
NPI 1821257205
$4,535.90
in general payments reported to CMS, 2019-2025
30 companies · $1,297 in 2025
The $1,297 reported for 2025 was more than what 83% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $672 · 2020: $399 · 2021: $417 · 2022: $370 · 2023: $400 · 2024: $981 · 2025: $1,297.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,439 · Education: $240.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,438.61 |
| Education | $239.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $529.27 | 2019-2025 | Farxiga, Lokelma |
| Amgen INC. | $403.41 | 2021-2025 | Krystexxa, Tavneos, Aranesp |
| Otsuka America Pharmaceutical, INC. | $399.81 | 2019-2025 | Jynarque, Voyxact |
| Opko Pharmaceuticals, LLC | $342.38 | 2019-2025 | Rayaldee |
| Calliditas Therapeutics US INC. | $305.96 | 2023-2025 | Tarpeyo |
| Glaxosmithkline, LLC. | $265.21 | 2020-2025 | Arexvy, Shingrix |
| Travere Therapeutics, INC. | $260.40 | 2023-2025 | Filspari |
| Vifor Pharma, INC. | $247.62 | 2019-2025 | Veltassa |
| Novartis Pharmaceuticals Corporation | $233.56 | 2024-2025 | |
| Baxter Healthcare | $217.06 | 2022 | |
| Fresenius USA Marketing, INC. | $175.45 | 2019-2025 | Velphoro, Velphoro |
| Horizon Therapeutics Plc | $149.76 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $147.88 | 2023-2024 | Soliris, Ultomiris |
| Mallinckrodt Hospital Products INC. | $104.26 | 2020-2022 | |
| Lilly USA, LLC | $93.74 | 2023-2025 | Jardiance |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Enterprises LLC | $91.18 | 2019 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $90.39 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $79.82 | 2024-2025 | Jardiance |
| Aurinia Pharma U.S., INC. | $74.03 | 2023-2025 | Lupkynis |
| Scpharmaceuticals INC. | $71.68 | 2025 | |
| Corcept Therapeutics | $51.88 | 2025 | Korlym |
| Leadiant Biosciences, INC. | $32.63 | 2023 | Carnitor |
| Genzyme Corporation | $27.52 | 2024 | |
| Ardelyx, INC. | $25.77 | 2023 | Ibsrela |
| Alnylam Pharmaceuticals INC. | $25.59 | 2023 | Givlaari |
| Akebia Therapeutics INC | $21.62 | 2025 | Vafseo |
| Takeda Pharmaceuticals U.S.A., INC. | $21.36 | 2022 | |
| Janssen Scientific Affairs, LLC | $18.92 | 2019 | |
| Daiichi Sankyo INC. | $16.26 | 2019 | |
| Shire North American Group INC | $11.48 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Salahuddin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.